Logo image of OBIO

ORCHESTRA BIOMED HOLDINGS IN (OBIO) Stock Fundamental Analysis

USA - NASDAQ:OBIO - US68572M1062 - Common Stock

3.94 USD
-0.24 (-5.74%)
Last: 11/14/2025, 8:11:49 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to OBIO. OBIO was compared to 189 industry peers in the Health Care Equipment & Supplies industry. OBIO may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, OBIO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year OBIO has reported negative net income.
In the past year OBIO has reported a negative cash flow from operations.
OBIO had negative earnings in each of the past 5 years.
OBIO had a negative operating cash flow in each of the past 5 years.
OBIO Yearly Net Income VS EBIT VS OCF VS FCFOBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -162.75%, OBIO is not doing good in the industry: 89.95% of the companies in the same industry are doing better.
OBIO's Return On Equity of -23626.78% is on the low side compared to the rest of the industry. OBIO is outperformed by 90.48% of its industry peers.
Industry RankSector Rank
ROA -162.75%
ROE -23626.78%
ROIC N/A
ROA(3y)-56.32%
ROA(5y)-79.02%
ROE(3y)-108.38%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OBIO Yearly ROA, ROE, ROICOBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

The Gross Margin of OBIO (92.66%) is better than 99.47% of its industry peers.
OBIO's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for OBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 92.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.78%
GM growth 5YN/A
OBIO Yearly Profit, Operating, Gross MarginsOBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 1K -1K 2K -2K

More info and screens

2

2. Health

2.1 Basic Checks

OBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
OBIO has more shares outstanding than it did 1 year ago.
OBIO has a worse debt/assets ratio than last year.
OBIO Yearly Shares OutstandingOBIO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
OBIO Yearly Total Debt VS Total AssetsOBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -13.09, we must say that OBIO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of OBIO (-13.09) is worse than 82.01% of its industry peers.
A Debt/Equity ratio of 48.76 is on the high side and indicates that OBIO has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 48.76, OBIO is doing worse than 89.95% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 48.76
Debt/FCF N/A
Altman-Z -13.09
ROIC/WACCN/A
WACC8.62%
OBIO Yearly LT Debt VS Equity VS FCFOBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 2.10 indicates that OBIO has no problem at all paying its short term obligations.
OBIO's Current ratio of 2.10 is on the low side compared to the rest of the industry. OBIO is outperformed by 61.38% of its industry peers.
OBIO has a Quick Ratio of 2.09. This indicates that OBIO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.09, OBIO is in line with its industry, outperforming 55.03% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.1
Quick Ratio 2.09
OBIO Yearly Current Assets VS Current LiabilitesOBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

OBIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -15.19%.
OBIO shows a strong growth in Revenue. In the last year, the Revenue has grown by 41.54%.
EPS 1Y (TTM)-15.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.11%
Revenue 1Y (TTM)41.54%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7.46%

3.2 Future

Based on estimates for the next years, OBIO will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.62% on average per year.
The Revenue is expected to grow by 80.89% on average over the next years. This is a very strong growth
EPS Next Y-8.67%
EPS Next 2Y4.16%
EPS Next 3Y9.64%
EPS Next 5Y14.62%
Revenue Next Year2.51%
Revenue Next 2Y6.61%
Revenue Next 3Y-6.05%
Revenue Next 5Y80.89%

3.3 Evolution

OBIO Yearly Revenue VS EstimatesOBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 50M 100M 150M
OBIO Yearly EPS VS EstimatesOBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

OBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OBIO Price Earnings VS Forward Price EarningsOBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OBIO Per share dataOBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.16%
EPS Next 3Y9.64%

More info and screens

0

5. Dividend

5.1 Amount

OBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORCHESTRA BIOMED HOLDINGS IN

NASDAQ:OBIO (11/14/2025, 8:11:49 PM)

3.94

-0.24 (-5.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)11-18 2025-11-18/amc
Inst Owners25.01%
Inst Owner Change0.87%
Ins Owners2.95%
Ins Owner Change5.69%
Market Cap212.60M
Revenue(TTM)2.94M
Net Income(TTM)-69.70M
Analysts81.54
Price Target13.77 (249.49%)
Short Float %1.86%
Short Ratio2.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.4%
Min EPS beat(2)0.13%
Max EPS beat(2)2.68%
EPS beat(4)4
Avg EPS beat(4)3.22%
Min EPS beat(4)0.13%
Max EPS beat(4)6.52%
EPS beat(8)7
Avg EPS beat(8)1.89%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)39.73%
Min Revenue beat(2)17.83%
Max Revenue beat(2)61.63%
Revenue beat(4)3
Avg Revenue beat(4)11.24%
Min Revenue beat(4)-70.51%
Max Revenue beat(4)61.63%
Revenue beat(8)3
Avg Revenue beat(8)-16.13%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.53%
EPS NQ rev (1m)5.29%
EPS NQ rev (3m)15.54%
EPS NY rev (1m)3.72%
EPS NY rev (3m)11.43%
Revenue NQ rev (1m)3.1%
Revenue NQ rev (3m)16.41%
Revenue NY rev (1m)1.67%
Revenue NY rev (3m)9.09%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 72.22
P/FCF N/A
P/OCF N/A
P/B 720.69
P/tB 720.69
EV/EBITDA N/A
EPS(TTM)-1.82
EYN/A
EPS(NY)-1.52
Fwd EYN/A
FCF(TTM)-1.12
FCFYN/A
OCF(TTM)-1.1
OCFYN/A
SpS0.05
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -162.75%
ROE -23626.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 92.66%
FCFM N/A
ROA(3y)-56.32%
ROA(5y)-79.02%
ROE(3y)-108.38%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.78%
GM growth 5YN/A
F-Score3
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 48.76
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 284.57%
Cap/Sales 31.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.1
Quick Ratio 2.09
Altman-Z -13.09
F-Score3
WACC8.62%
ROIC/WACCN/A
Cap/Depr(3y)194.88%
Cap/Depr(5y)224.07%
Cap/Sales(3y)17.77%
Cap/Sales(5y)19.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.11%
EPS Next Y-8.67%
EPS Next 2Y4.16%
EPS Next 3Y9.64%
EPS Next 5Y14.62%
Revenue 1Y (TTM)41.54%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7.46%
Revenue Next Year2.51%
Revenue Next 2Y6.61%
Revenue Next 3Y-6.05%
Revenue Next 5Y80.89%
EBIT growth 1Y-22.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-21.23%
EBIT Next 3Y-10.36%
EBIT Next 5Y2.29%
FCF growth 1Y-46.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-45.29%
OCF growth 3YN/A
OCF growth 5YN/A

ORCHESTRA BIOMED HOLDINGS IN / OBIO FAQ

Can you provide the ChartMill fundamental rating for ORCHESTRA BIOMED HOLDINGS IN?

ChartMill assigns a fundamental rating of 2 / 10 to OBIO.


What is the valuation status of ORCHESTRA BIOMED HOLDINGS IN (OBIO) stock?

ChartMill assigns a valuation rating of 0 / 10 to ORCHESTRA BIOMED HOLDINGS IN (OBIO). This can be considered as Overvalued.


Can you provide the profitability details for ORCHESTRA BIOMED HOLDINGS IN?

ORCHESTRA BIOMED HOLDINGS IN (OBIO) has a profitability rating of 1 / 10.


What is the earnings growth outlook for ORCHESTRA BIOMED HOLDINGS IN?

The Earnings per Share (EPS) of ORCHESTRA BIOMED HOLDINGS IN (OBIO) is expected to decline by -8.67% in the next year.